Zacks Investment Research cut shares of Editas Medicine, Inc. (NASDAQ:EDIT) from a buy rating to a hold rating in a report released on Monday.

According to Zacks, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. “

Several other analysts also recently weighed in on the stock. Cann started coverage on shares of Editas Medicine in a research report on Monday, July 17th. They issued a market perform rating on the stock. Barclays PLC started coverage on shares of Editas Medicine in a research report on Wednesday, September 6th. They issued an overweight rating and a $28.00 price objective on the stock. ValuEngine downgraded shares of Editas Medicine from a hold rating to a sell rating in a research report on Wednesday, October 25th. Oppenheimer Holdings, Inc. reiterated a market perform rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Finally, J P Morgan Chase & Co set a $27.00 price objective on shares of Editas Medicine and gave the company a hold rating in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Editas Medicine has a consensus rating of Hold and a consensus price target of $26.73.

Shares of Editas Medicine (NASDAQ:EDIT) opened at $24.34 on Monday. Editas Medicine has a 52-week low of $13.12 and a 52-week high of $29.20. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.04). The firm had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The company’s revenue for the quarter was up 553.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.59) earnings per share. sell-side analysts expect that Editas Medicine will post -2.92 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/editas-medicine-inc-edit-downgraded-by-zacks-investment-research/1706006.html.

In other Editas Medicine news, CEO Katrine Bosley sold 10,000 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $20.42, for a total transaction of $204,200.00. Following the sale, the chief executive officer now directly owns 1,414,629 shares in the company, valued at approximately $28,886,724.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 43,332 shares of company stock worth $946,504 over the last 90 days. 19.40% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. IHT Wealth Management LLC bought a new stake in shares of Editas Medicine during the 2nd quarter worth about $107,000. Great West Life Assurance Co. Can raised its position in shares of Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after buying an additional 4,159 shares in the last quarter. Bank of America Corp DE raised its position in shares of Editas Medicine by 72.2% during the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after buying an additional 2,489 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Editas Medicine during the 2nd quarter worth about $127,000. Finally, Legal & General Group Plc raised its position in shares of Editas Medicine by 308.4% during the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after buying an additional 6,535 shares in the last quarter. Institutional investors own 67.17% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.